Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a recent update, Eli Lilly and Company ...

Colorectal cancer (CRC) is a significant global health concern, originating from precancerous polyps in the colon or rectum and progressing through ...

Immuneering (NASDAQ:IMRX) said it has entered into a clinical supply agreement with Eli Lilly (NYSE:LLY) for its cancer drug ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

© 2001-2025 Plasteurope.com | Imprint | Privacy | Cookie settings ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

The awardees were celebrated for their life-bettering products at a banquet in Washington, DC, on Tuesday, Aug. 19 ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

The firm is advancing ELI-002 after seeing a positive Phase I readout this month and is expecting initial results from a randomized Phase II study this year.

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Dubbed the ‘guardian of the genome’, the p53 protein responds to DNA damage by stalling cell division, initiating DNA repair ...